Implementing the additional strength biowaiver for generics: EMA recommended approaches and challenges for a US-FDA submission.

Eur J Pharm Sci

Translational Medicine, Merck & Co., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA.

Published: January 2018

This review describes the EMA requirements on biowaivers for additional strengths of immediate release and modified release oral solid dosage forms focused on generic applications and highlights the challenges for a simultaneous EMA and FDA submission. Some specificities of the current EMA guidelines are compared with the current FDA Guidance for Industry, with a special focus on the strength to be investigated in vivo, formulation suitability for biowaiver, and optimizing dissolution studies for additional strength biowaivers. In Europe, the same principles applied for generics may be considered for deriving the biowaivers for innovator products. Several case studies are presented to illustrate the challenges of applying for additional strength biowaivers in EMA and FDA simultaneously.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejps.2017.10.013DOI Listing

Publication Analysis

Top Keywords

additional strength
12
ema fda
8
strength biowaivers
8
ema
5
implementing additional
4
strength
4
strength biowaiver
4
biowaiver generics
4
generics ema
4
ema recommended
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!